{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:05:12Z","timestamp":1793397912535,"version":"4.5.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF21OC0069257"],"award-info":[{"award-number":["NNF21OC0069257"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF220C0077221"],"award-info":[{"award-number":["NNF220C0077221"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AP Moller Foundation"},{"DOI":"10.13039\/501100004785","name":"NordForsk","doi-asserted-by":"publisher","award":["105545"],"award-info":[{"award-number":["105545"]}],"id":[{"id":"10.13039\/501100004785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Independent Research Fund Denmark","doi-asserted-by":"publisher","award":["8045-00047B"],"award-info":[{"award-number":["8045-00047B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>STUDY QUESTION<\/jats:title>\n                    <jats:p>What is the association between periconceptional GLP-1 receptor agonist exposure and risk of obstetric complications?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUMMARY ANSWER<\/jats:title>\n                    <jats:p>Periconceptional GLP-1 receptor agonist exposure was associated with increased preterm birth risk when used for diabetes treatment (liraglutide aOR 1.70, 95% CI 1.17\u20132.48; semaglutide aOR 1.84, 95% CI 1.24\u20132.7) but not for weight management, suggesting the underlying diabetes rather than the medication may be the causal factor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                    <jats:p>GLP-1 receptor agonists are rapidly expanding in use among reproductive-age women for diabetes and obesity treatment. While not approved for use in pregnancy, inadvertent periconceptional exposure occurs frequently. Limited safety data exist, with recent small studies suggesting no increased risk of major congenital malformations, but comprehensive obstetric outcome data remain lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                    <jats:p>This nationwide observational cohort study used data from Danish health registries from October 2009 through December 2023. We analyzed 756\u00a0636 singleton pregnancies among 480\u00a0231 women, with 529 pregnancies having periconceptional GLP-1 receptor agonist exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                    <jats:p>We identified periconceptional liraglutide or semaglutide exposure (prescription redemption within 8\u2009weeks before\/after last menstrual period) using the National Prescription Register. Exposed pregnancies were stratified by maternal pre-existing diabetes status and compared with propensity score-matched unexposed controls. Propensity score matching incorporated maternal age, BMI, smoking, geographic region, education, pre-existing diabetes, parity, and temporal factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                    <jats:p>Before adjustment, exposed women had higher rates of multiple obstetric complications. After propensity score matching, only the risk of preterm birth remained elevated for exposed women. This increased risk was confined to women using GLP-1 receptor agonists for diabetes treatment (liraglutide aOR 1.70, 95% CI 1.17\u20132.48; semaglutide aOR 1.84, 95% CI 1.24\u20132.71). Among women without pre-existing diabetes using these medications for weight management, no association with preterm birth was observed (liraglutide aOR 1.01, 95% CI 0.58\u20131.76; semaglutide aOR 0.71, 95% CI 0.30\u20131.70).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                    <jats:p>Study limitations include the absence of data regarding medication compliance post prescription redemption, potential misclassification due to parallel importation, and the inability to control for unmeasured confounding factors. The observational design cannot establish causality. Most semaglutide weight-loss prescriptions occurred late in the study period, limiting long-term follow-up data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                    <jats:p>The results are compatible with the hypothesis that diabetes-related factors, rather than GLP-1 receptor agonist exposure itself, may contribute to the increased preterm birth risk. If so, there are important implications for preconception counselling and may inform future guidelines for GLP-1 receptor agonist use in reproductive-age women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                    <jats:p>KVRH, KB, DW, and HSN acknowledge funding from the Novo Nordisk Foundation (NNF21OC0069257 and NNF220C0077221) and the AP Moller Foundation. LMH was supported in part by grants from NordForsk (id: 105545), the Novo Nordisk Foundation (NNF17OC0027594 and NNF17OC0027812), and the Villum Foundation (\u2018Nation-Scale Social Networks\u2019). KSL was supported by the Independent Research Fund Denmark (8045-00047B), NordForsk (id: 156298), and Centre for Childhood Health (id: 72 2024_F_008 and 2024_I_001). SM: Advisory boards: AstraZeneca, Boehringer Ingelheim, Intarcia Therapeutics, Novo Nordisk, Sanofi, Abbott Lab, Bayer, Amgen; Lecture fees: AstraZeneca, Novo Nordisk, MSD; Research grant recipient: Novo Nordisk; Novo Nordisk foundation, Boehringer Ingelheim; Support for attending meetings and\/or travel: Novo Nordisk, Boehringer-Ingelheim, Bayer. Grants were paid to the institution, Hvidovre Hospital, University of Copenhagen, with no personal fee. None of the grants has any relation to the work presented in the paper. SM is also a consultant for Netdoktor and has served as principal investigator in relation to the development of drugs for the treatment of type 2 diabetes and obesity in collaboration with Novo Nordisk and Bayer, with funds paid to the institution where he is employed, with no personal fee and with no relation to the work reported in this article. HSN: lecture fees on own research: Novo Nordisk A\/S, Ferring Pharmaceuticals, Merck A\/S, Astra Zeneca, Cook Medical, Gedeon Richter and Ibsa Nordic. K.B holds stock\/share or stock\/share options with Novonesis, Genmab, and Novo Nordisk (held in personal investment portfolio). The remaining authors have no other disclosures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                    <jats:p>N\/A<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/hropen\/hoag015","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:07:00Z","timestamp":1773792420000},"source":"Crossref","is-referenced-by-count":14,"title":["Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study"],"prefix":"10.1093","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1172-6099","authenticated-orcid":false,"given":"Kathrine Vauvert R","family":"Hviid","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, Copenhagen University Hospital Hvidovre , Hvidovre,","place":["Denmark"]},{"name":"Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2489-2499","authenticated-orcid":false,"given":"Karina","family":"Banasik","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Copenhagen University Hospital Hvidovre , Hvidovre,","place":["Denmark"]},{"name":"Department of Health Technology, Technical University of Denmark , Lyngby,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6399-495X","authenticated-orcid":false,"given":"Laust Hvas","family":"Mortensen","sequence":"additional","affiliation":[{"name":"Methods and Analysis, Statistics Denmark , Copenhagen,","place":["Denmark"]},{"name":"Department of Public Health, University of Copenhagen , Copenhagen,","place":["Denmark"]},{"name":"ROCKWOOL Foundation Research Unit , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-1815","authenticated-orcid":false,"given":"Sten","family":"Madsbad","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen,","place":["Denmark"]},{"name":"Department of Endocrinology, Copenhagen University Hospital Hvidovre , Hvidovre,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7061-3767","authenticated-orcid":false,"given":"Katrine","family":"Strandberg-Larsen","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Copenhagen , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8063-5820","authenticated-orcid":false,"given":"Nina Rica Wium","family":"Geiker","sequence":"additional","affiliation":[{"name":"Centre for Childhood Health , Copenhagen,","place":["Denmark"]},{"name":"Department of Nutrition, Exercise and Sports, University of Copenhagen , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0128-8432","authenticated-orcid":false,"given":"David","family":"Westergaard","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Copenhagen University Hospital Hvidovre , Hvidovre,","place":["Denmark"]},{"name":"Department of Health Technology, Technical University of Denmark , Lyngby,","place":["Denmark"]},{"name":"Methods and Analysis, Statistics Denmark , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-8103","authenticated-orcid":false,"given":"Henriette Svarre","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Copenhagen University Hospital Hvidovre , Hvidovre,","place":["Denmark"]},{"name":"Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"2026041314450881100_hoag015-B1","doi-asserted-by":"crossref","first-page":"e077","DOI":"10.1097\/og9.0000000000000077","article-title":"Exposure to high-dose liraglutide in a pregnant woman with obesity","volume":"2","author":"Abushanab","year":"2025","journal-title":"O G Open"},{"key":"2026041314450881100_hoag015-B2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/humupd\/dmx027","article-title":"How effective are weight-loss interventions for improving fertility in women and men who are overweight or obese? A systematic review and meta-analysis of the evidence","volume":"23","author":"Best","year":"2017","journal-title":"Hum Reprod Update"},{"key":"2026041314450881100_hoag015-B3","first-page":"1","article-title":"mice: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Soft"},{"key":"2026041314450881100_hoag015-B4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","article-title":"Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy","volume":"184","author":"Cesta","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2026041314450881100_hoag015-B5","author":"Dansk Endokrinologisk Selskab","year":"2023"},{"key":"2026041314450881100_hoag015-B6","doi-asserted-by":"crossref","first-page":"e083550","DOI":"10.1136\/bmjopen-2023-083550","article-title":"Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services","volume":"14","author":"Dao","year":"2024","journal-title":"BMJ Open"},{"key":"2026041314450881100_hoag015-B7","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"2026041314450881100_hoag015-B8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-90-481-9485-8_20","article-title":"The prevalence of congenital anomalies in Europe","volume":"686","author":"Dolk","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"2026041314450881100_hoag015-B9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajog.2024.08.024","article-title":"Glucagon-like peptide-1 receptor agonist use in pregnancy: a review","volume":"232","author":"Drummond","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"2026041314450881100_hoag015-B10","author":"European Medicines Agency","year":"2019"},{"key":"2026041314450881100_hoag015-B11","author":"European Medicines Agency","year":"2022"},{"key":"2026041314450881100_hoag015-B12","author":"European Medicines Agency","year":"2022"},{"key":"2026041314450881100_hoag015-B13","author":"European Medicines Agency","year":"2024"},{"key":"2026041314450881100_hoag015-B14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/AOG.0000000000005825","article-title":"Role of glucagon-like peptide-1 receptor agonists in people with infertility and pregnancy","volume":"145","author":"Finkle","year":"2025","journal-title":"Obstet Gynecol"},{"key":"2026041314450881100_hoag015-B15","author":"Food and Drug Administration (FDA)","year":"2017"},{"key":"2026041314450881100_hoag015-B16","author":"Food and Drug Administration (FDA)","year":"2023"},{"key":"2026041314450881100_hoag015-B17","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3389\/fimmu.2018.01291","article-title":"Inflammation-induced adverse pregnancy and neonatal outcomes can be improved by the immunomodulatory peptide exendin-4","volume":"9","author":"Garcia-Flores","year":"2018","journal-title":"Front Immunol"},{"key":"2026041314450881100_hoag015-B18","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"2026041314450881100_hoag015-B19","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/dme.12726","article-title":"Normal pregnancy outcome after first-trimester exposure to liraglutide in a woman with type 2 diabetes","volume":"32","author":"Greco","year":"2015","journal-title":"Diabet Med"},{"key":"2026041314450881100_hoag015-B20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.amjcard.2025.03.013","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonist use during the first trimester in pregnant women with type 2 diabetes","volume":"246","author":"Hanif","year":"2025","journal-title":"Am J Cardiol"},{"key":"2026041314450881100_hoag015-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Soft"},{"key":"2026041314450881100_hoag015-B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/obr.13325","article-title":"The effectiveness of weight-loss lifestyle interventions for improving fertility in women and men with overweight or obesity and infertility: a systematic review update of evidence from randomized controlled trials","volume":"22","author":"Hunter","year":"2021","journal-title":"Obesity Reviews"},{"key":"2026041314450881100_hoag015-B23","first-page":"116.e1-116","article-title":"Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomes","volume":"233","author":"Imbroane","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"2026041314450881100_hoag015-B24","first-page":"70","article-title":"Pregnancy outcome and liraglutide levels in serum and umbilical vein blood of a woman with type 2 diabetes. A case report","volume":"27","author":"Ivani\u0161evi\u0107","year":"2018","journal-title":"Gynaecol Perinatol"},{"key":"2026041314450881100_hoag015-B25","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.2337\/diacare.27.12.2819","article-title":"Outcomes in type 1 diabetic pregnancies","volume":"27","author":"Jensen","year":"2004","journal-title":"Diabetes Care"},{"key":"2026041314450881100_hoag015-B26","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1111\/apa.17412","article-title":"Exposure to GLP-1 receptor agonists in early pregnancy did not increase the risk of congenital malformations","volume":"113","author":"Kuitunen","year":"2024","journal-title":"Acta Paediatr"},{"key":"2026041314450881100_hoag015-B27","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/oby.22794","article-title":"Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5","volume":"28","author":"Kushner","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"2026041314450881100_hoag015-B28","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.2337\/dc24-1082","article-title":"Real-world use of semaglutide for weight management: patient characteristics and dose titration: a Danish cohort study","volume":"47","author":"Ladebo","year":"2024","journal-title":"Diabetes Care [ Care"},{"key":"2026041314450881100_hoag015-B29","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026041314450881100_hoag015-B30","doi-asserted-by":"crossref","first-page":"691","DOI":"10.7326\/M18-1974","article-title":"Maternal glycemic control in type 1 diabetes and the risk for preterm birth: a population-based cohort study","volume":"170","author":"Ludvigsson","year":"2019","journal-title":"Ann Intern Med"},{"key":"2026041314450881100_hoag015-B31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/obr.12288","article-title":"Risks associated with obesity in pregnancy, for the mother and baby: a systematic review of reviews","volume":"16","author":"Marchi","year":"2015","journal-title":"Obes Rev"},{"key":"2026041314450881100_hoag015-B32","doi-asserted-by":"crossref","first-page":"e12690","DOI":"10.1111\/cob.12690","article-title":"What is known about the use of weight loss medication in women with overweight\/obesity on fertility and reproductive health outcomes? A scoping review","volume":"14","author":"Maslin","year":"2024","journal-title":"Clin Obes"},{"key":"2026041314450881100_hoag015-B33","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1001\/jama.2025.20951","article-title":"Gestational weight gain and pregnancy outcomes after GLP-1 receptor agonist discontinuation","volume":"334","author":"Maya","year":"2025","journal-title":"JAMA"},{"key":"2026041314450881100_hoag015-B34","author":"M\u00f8ller","year":"2024"},{"key":"2026041314450881100_hoag015-B35","doi-asserted-by":"crossref","first-page":"1215356","DOI":"10.3389\/fendo.2023.1215356","article-title":"Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence","volume":"14","author":"Muller","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026041314450881100_hoag015-B36","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity. 2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","author":"Ng","year":"2025","journal-title":"The Lancet"},{"key":"2026041314450881100_hoag015-B37","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/ajcn\/87.6.1750","article-title":"Combined associations of prepregnancy body mass index and gestational weight gain with the outcome of pregnancy","volume":"87","author":"Nohr","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"2026041314450881100_hoag015-B38","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s13669-023-00350-1","article-title":"Pharmacologic treatment of obesity in reproductive aged women","volume":"12","author":"Nuako","year":"2023","journal-title":"Curr Obstet Gynecol Rep [ Rep"},{"key":"2026041314450881100_hoag015-B39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/bdrc.21090","article-title":"Effect of maternal diabetes on the embryo, fetus, and children: congenital anomalies, genetic and epigenetic changes and developmental outcomes","volume":"105","author":"Ornoy","year":"2015","journal-title":"Birth Defects Res C Embryo Today"},{"key":"2026041314450881100_hoag015-B40","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1111\/dom.16437","article-title":"Le Glucagon-like peptide 1 (GLP-1) receptor agonists\u2019 use during pregnancy: safety data from regulatory clinical trials","volume":"27","author":"Parker","year":"2025","journal-title":"Diabetes Obesity Metabolism"},{"key":"2026041314450881100_hoag015-B42","author":"PDB-101","year":"2025"},{"key":"2026041314450881100_hoag015-B41","author":"PDB-101: Protein Data Bank","year":"2025"},{"key":"2026041314450881100_hoag015-B43","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S2213-8587(16)30217-0","article-title":"Preconceptional and maternal obesity: epidemiology and health consequences","volume":"4","author":"Poston","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026041314450881100_hoag015-B44","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.fertnstert.2020.06.033","article-title":"Time to pregnancy after a prepregnancy very-low-energy diet program in women with obesity: substudy of a randomized controlled trial","volume":"114","author":"Price","year":"2020","journal-title":"Fertil Steril"},{"key":"2026041314450881100_hoag015-B45","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00404-024-07849-9","article-title":"Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review","volume":"311","author":"Price","year":"2025","journal-title":"Arch Gynecol Obstet"},{"key":"2026041314450881100_hoag015-B46","author":"R Core Team","year":"2021"},{"key":"2026041314450881100_hoag015-B47","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"2026041314450881100_hoag015-B48","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1017\/pan.2020.32","article-title":"Generalized full matching","volume":"29","author":"S\u00e4vje","year":"2021","journal-title":"Polit Anal"},{"key":"2026041314450881100_hoag015-B49","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41430-021-00902-9","article-title":"Preconceptional maternal weight loss and hypertensive disorders in pregnancy: a systematic review and meta-analysis","volume":"75","author":"Schenkelaars","year":"2021","journal-title":"Eur J Clin Nutr"},{"key":"2026041314450881100_hoag015-B50","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ijgo.15092","article-title":"Semaglutide and pregnancy","volume":"163","author":"Skov","year":"2023","journal-title":"Intl J Gynecology Obste"},{"key":"2026041314450881100_hoag015-B51","first-page":"324","volume-title":"Hum Reprod","author":"Steeg","year":"2008"},{"key":"2026041314450881100_hoag015-B52","author":"Sundhedsdatabanken","year":"2025"},{"key":"2026041314450881100_hoag015-B53","author":"Sundhedsstyrelsen Jensen","year":"2022"},{"key":"2026041314450881100_hoag015-B54","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04332.x","article-title":"Prescribing without evidence: pregnancy","volume":"74","author":"Thomas","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"2026041314450881100_hoag015-B55","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/OGX.0000000000000899","article-title":"Diagnosis and management of gestational diabetes mellitus: an overview of national and international guidelines","volume":"76","author":"Tsakiridis","year":"2021","journal-title":"Obstet Gynecol Surv"},{"key":"2026041314450881100_hoag015-B56","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"2026041314450881100_hoag015-B57","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"key":"2026041314450881100_hoag015-B58","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2026041314450881100_hoag015-B59","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1002\/oby.23842","article-title":"Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity","volume":"31","author":"Wilkinson","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"2026041314450881100_hoag015-B60","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/humrep\/dep360","article-title":"An internet-based prospective study of body size and time-to-pregnancy","volume":"25","author":"Wise","year":"2010","journal-title":"Hum Reprod"},{"key":"2026041314450881100_hoag015-B61","author":"World Health Organization","year":"2022"},{"key":"2026041314450881100_hoag015-B62","author":"World Obesity Federation","year":"2022"},{"key":"2026041314450881100_hoag015-B63","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1152\/ajpheart.00486.2019","article-title":"The glucagon-like peptide 1 receptor agonist liraglutide attenuates placental ischemia-induced hypertension","volume":"318","author":"Younes","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"}],"container-title":["Human Reproduction Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/hropen\/article-pdf\/2026\/2\/hoag015\/67383269\/hoag015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/hropen\/article-pdf\/2026\/2\/hoag015\/67383269\/hoag015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T18:45:18Z","timestamp":1776105918000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hropen\/article\/doi\/10.1093\/hropen\/hoag015\/8526483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,12]]}},"URL":"https:\/\/doi.org\/10.1093\/hropen\/hoag015","relation":{},"ISSN":["2399-3529"],"issn-type":[{"value":"2399-3529","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"hoag015"}}